• Zenas Biopharma outlined plans for global marketing submissions for obexelimab in IgG4-related disease, with FDA BLA filing targeted for Q2 2026 and EMA MAA filing targeted for H2 2026.
• Phase 3 INDIGO trial in IgG4-RD met primary endpoint, cutting flare risk 56% versus placebo (HR 0.443; p=0.0005); 73% of treated patients remained flare-free through week 52.
• Safety profile in INDIGO showed serious adverse events at 10% versus 19% for placebo; grade 3 infections ran 2% versus 4%.
• Multiple sclerosis program orelabrutinib advanced with Phase 3 trials initiated in PPMS in Q3 2025 and naSPMS in Q1 2026.
• Pipeline updates included Phase 2 SLE topline data for obexelimab expected in Q4 2026; early-stage assets ZB021, ZB022, ZB014 guided to initial clinical readouts from late 2026 into 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.